The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial

A return to first principles

Kiran Musunuru, Roger S Blumenthal

Research output: Contribution to journalArticle

Abstract

To outward appearances, the publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has led to a monolithic backlash against the use of ezetimibe by cardiologists for the treatment of hyperlipidemia. Rather than be swayed by popular opinion, we should each put the results of ENHANCE into context and ask the questions: should I put my trust in an imaging surrogate or in low-density lipoprotein (LDL) cholesterol (LDL-C), and how do the safety and efficacy of ezetimibe compare with other nonstatin lipid-lowering agents?

Original languageEnglish (US)
Pages (from-to)288-290
Number of pages3
JournalClinical Cardiology
Volume31
Issue number6
DOIs
StatePublished - Jun 2008

Fingerprint

Simvastatin
Hypercholesterolemia
Atherosclerosis
Hyperlipidemias
LDL Cholesterol
Publications
Lipids
Safety
Ezetimibe
Therapeutics

Keywords

  • ENHANCE trial
  • Ezetimibe
  • Hypercholesterolemia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{469fb540ba8d4caaba171b834ddf67a0,
title = "The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: A return to first principles",
abstract = "To outward appearances, the publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has led to a monolithic backlash against the use of ezetimibe by cardiologists for the treatment of hyperlipidemia. Rather than be swayed by popular opinion, we should each put the results of ENHANCE into context and ask the questions: should I put my trust in an imaging surrogate or in low-density lipoprotein (LDL) cholesterol (LDL-C), and how do the safety and efficacy of ezetimibe compare with other nonstatin lipid-lowering agents?",
keywords = "ENHANCE trial, Ezetimibe, Hypercholesterolemia",
author = "Kiran Musunuru and Blumenthal, {Roger S}",
year = "2008",
month = "6",
doi = "10.1002/clc.20405",
language = "English (US)",
volume = "31",
pages = "288--290",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial

T2 - A return to first principles

AU - Musunuru, Kiran

AU - Blumenthal, Roger S

PY - 2008/6

Y1 - 2008/6

N2 - To outward appearances, the publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has led to a monolithic backlash against the use of ezetimibe by cardiologists for the treatment of hyperlipidemia. Rather than be swayed by popular opinion, we should each put the results of ENHANCE into context and ask the questions: should I put my trust in an imaging surrogate or in low-density lipoprotein (LDL) cholesterol (LDL-C), and how do the safety and efficacy of ezetimibe compare with other nonstatin lipid-lowering agents?

AB - To outward appearances, the publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has led to a monolithic backlash against the use of ezetimibe by cardiologists for the treatment of hyperlipidemia. Rather than be swayed by popular opinion, we should each put the results of ENHANCE into context and ask the questions: should I put my trust in an imaging surrogate or in low-density lipoprotein (LDL) cholesterol (LDL-C), and how do the safety and efficacy of ezetimibe compare with other nonstatin lipid-lowering agents?

KW - ENHANCE trial

KW - Ezetimibe

KW - Hypercholesterolemia

UR - http://www.scopus.com/inward/record.url?scp=46949084239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46949084239&partnerID=8YFLogxK

U2 - 10.1002/clc.20405

DO - 10.1002/clc.20405

M3 - Article

VL - 31

SP - 288

EP - 290

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 6

ER -